IMUNON Appoints Stacy R. Lindborg As President And CEO, Effective May 13, 2024
IMUNON Appoints Stacy R. Lindborg As President And CEO, Effective May 13, 2024
IMUNON 任命 Stacy R. Lindborg 为总裁兼首席执行官，自 2024 年 5 月 13 日起生效
Assumes leadership role as Company anticipates multiple near-term clinical milestones
Brings extensive leadership and experience in drug development and business strategy
LAWRENCEVILLE, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, today announced the appointment of Stacy R. Lindborg, Ph.D. as President and Chief Executive Officer, effective May 13, 2024. Dr. Lindborg has served on IMUNON's board of directors since 2021.
Dr. Lindborg assumes the leadership of IMUNON at a pivotal time. Topline results from the Phase 2 OVATION 2 Study with IMUNON's...
登录免费看全文
登录/注册